Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for osteoporosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Options for osteoporosis Options for osteoporosis Options for osteoporosis Martin-Stone S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Martin-Stone S. Options for osteoporosis. University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new (...) . Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Osteoporosis Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: firstname.lastname@example.org AccessionNumber 32003000786 Date bibliographic
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass without causing hypercalcemia, but their effects on fractures are unknown.We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women (...) points in the lumbar spine and by 3 and 6 more percentage points in the femoral neck; the 40-microg dose decreased bone mineral density at the shaft of the radius by 2 more percentage points. Both doses increased total-body bone mineral by 2 to 4 more percentage points than did placebo. Parathyroid hormone had only minor side effects (occasional nausea and headache).Treatment of postmenopausal osteoporosis with parathyroid hormone (1-34) decreases the risk of vertebral and nonvertebral fractures
Water fluoridation, osteoporosis, fractures: recent developments Water fluoridation, osteoporosis, fractures: recent developments Water fluoridation, osteoporosis, fractures: recent developments Demos L L, Kazda H, Cicuttini F M, Sinclair M I, Fairley C K Authors' objectives To review studies published since the 1991 National Health and Medical Research Council report on the effect of fluoride on bone strength, mass, and fracture rate (see Other Publications of Related Interest). Searching (...) MEDLINE was searched from 1991 to December 1998 for studies published in the English language. The keywords used in combination with 'fluoride' were 'bone', 'osteoporosis' and 'fractures'. The reference lists of the identified studies were also examined. Study selection Study designs of evaluations included in the review The studies of humans included controlled clinical trials, before-and-after studies, case-control studies, cohort studies, cross-sectional studies and ecological studies. Specific
Osteoporosis Prevention, Diagnosis, and Therapy Cover 1 49,896 Osteoporosis 3/6/01, 10:56 AM 51 NIH Consensus Statement Volume 17, Number 1 March 27–29, 2000 Osteoporosis Prevention, Diagnosis, and Therapy NATIONAL INSTITUTES OF HEALTH Office of the Director Cover 2 49,896 Osteoporosis 3/6/01, 10:14 AM 52 About the NIH Consensus Development Program NIH Consensus Development Conferences are convened to evalu ate available scientific information and resolve safety and efficacy issues related (...) that are part of the public session, and (3) closed deliberations by the panel during the remain der of the second day and morning of the third. This statement is an independent report of the consensus panel and is not a policy statement of the NIH or the Federal Government. Reference Information For making bibliographic reference to this consensus statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution: Osteoporosis
Fluoride for treating postmenopausal osteoporosis. To assess the efficacy of fluoride therapy on bone loss, vertebral and non-vertebral fractures and side effects in postmenopausal women.We searched Medline, Current Contents and the Cochrane Controlled Trial Registry up to December 1998.Two independent reviewers selected RCTs which met predetermined inclusion criteria.Two reviewers independently extracted data using predetermined forms and assessed the methodological quality of the trials using
Bisphosphonates for steroid induced osteoporosis. To assess the effects of bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis.We searched the Cochrane Musculoskeletal Group trials register, Medline up to 1997 and Embase1988-1997), and selected hand searching of reference lists was conducted. Hand searching of scientific abstracts from relevant meetings for the last five years was also done. An electronic search in Current Contents was done for the last six (...) months. The Cochrane Controlled Trials Register (CCTR) will be searched for future updates. All languages were included in the search. For practical reasons only those in English were included, but all languages will be retrieved and translated for future updates.All controlled clinical trials (CCTs) dealing with prevention or treatment of corticosteroid-induced osteoporosis with bisphosphonates of any type and reporting the outcomes of interest were assessed. Trials had to involve adults only
Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Corticosteroid-induced osteoporosis is a cause of morbidity in patients with chronic obstructive lung disease, asthma, and rheumatologic disorders. Corticosteroid treatment causes bone loss by a variety of complex mechanisms. It has been shown that bone mineral loss at the hip averages 14% in the first year after starting corticosteroid therapy.To review the efficacy of calcitonin (subcutaneous or nasal (...) year of glucocorticoid therapy at the lumbar spine by about 3% compared to placebo, but not at the femoral neck. Our analysis suggests that the protective effect on bone mass may be greater for the treatment of patients who have been taking corticosteroids for more than three months. Efficacy of calcitonin for fracture prevention in steroid-induced osteoporosis remains to be established.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Due to their known effects on bone metabolism, Vitamin D and related compounds have been proposed for the prevention of osteoporosis and fractures.To determine the effects of supplementation with Vitamin D or a Vitamin D analogue in the prevention of fractures of the axial and appendicular skeleton in elderly men or women with involutional or post-menopausal osteoporosis.We
Calcium and vitamin D for corticosteroid-induced osteoporosis. To assess the effects of calcium and vitamin D compared to calcium alone or placebo in the prevention of bone loss in patients taking systemic corticosteroids.We searched the Cochrane Musculoskeletal trials register, Cochrane Controlled Trials Register, EMBASE and Medline up to 1996. We also conducted a hand search of abstracts from various scientific meetings and reference lists of selected trials.All randomized trials comparing
Prevention and treatment of osteoporosis: consensus conference Prevention and treatment of osteoporosis: consensus conference Prevention and treatment of osteoporosis: consensus conference Israeli Center for Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Israeli Center for Technology Assessment (...) in Health Care. Prevention and treatment of osteoporosis: consensus conference. Israel Center for Technology Assessment in Health Care (ICTAHC). 2000 Authors' objectives This conference aimed to clarify aspects connected with the prevention, diagnosis and treatment of osteoporosis, and to formulate a recommendation for a national policy on the subject. This document presents the main points of the discussions and the recommendations. Indexing Status Subject indexing assigned by CRD MeSH Osteoporosis
Densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women Densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women Densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Institute for Clinical Systems Improvement. Densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2000 Authors' objectives This review aims to assess the available evidence on the effectiveness of densitometry as a diagnostic tool for the identification and treatment of osteoporosis in women. Authors' conclusions The ICSI Technology Assessment Committee finds
Alendronate for the treatment of osteoporosis in men. Despite its association with disability, death, and increased medical costs, osteoporosis in men has been relatively neglected as a subject of study. There have been no large, controlled trials of treatment in men.In a two-year double-blind trial, we studied the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men (age, 31 to 87 years; mean, 63) with osteoporosis. Approximately one third had low serum (...) free testosterone concentrations at base line; the rest had normal concentrations. Men with other secondary causes of osteoporosis were excluded. All the men received calcium and vitamin D supplements. The main outcome measures were the percent changes in lumbar-spine, hip, and total-body bone mineral density.The men who received alendronate had a mean (+/-SE) increase in bone mineral density of 7.1+/-0.3 percent at the lumbar spine, 2.5+/-0.4 percent at the femoral neck, and 2.0+/-0.2 percent
Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. The principle of "regression to the mean" predicts that patients with unusual responses to treatment might represent outliers who are likely to have more typical responses if treatment is continued without change.To test whether women who lose bone mineral density (BMD) during the first year of treatment for osteoporosis continue to lose BMD (...) ), and postmenopausal women with osteoporosis assigned to treatment with 60 or 120 mg/d of raloxifene hydrochloride in the Multiple Outcomes of Raloxifene Evaluation trial who similarly completed 2 years of monitoring while adhering to study medication (n = 3954).Baseline, 12-, and 24-month hip and spine BMD.Women with the greatest loss of BMD during the first year of treatment were the most likely to gain BMD during continued treatment. Specifically, among women taking alendronate whose hip BMD decreased by more
Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents Preventing fractures in postmenopausal women with osteoporosis: a review of recent controlled trials of antiresorptive agents Hochberg M Authors' objectives To review and summarise the evidence from randomised controlled trials (RCTs (...) ), of the ability of antiresorptive treatments to reduce the risk of fractures in postmenopausal women with osteoporosis. Searching A previous systematic review to October 1998 (see Other Publications of Related Interest) was updated by searching MEDLINE and Current Contents from October 1998 to December 1999. The reference lists of retrieved articles and review articles were considered. Conference proceedings published in the Journal of Bone and Mineral Research, Osteoporosis International, Calcified Tissue
Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis Blair M M, Carson D S, Barrington R Authors' objectives To summarise the literature concerning the use of bisphosphonates in the prevention and treatment of corticosteroid-induced osteoporosis, and to make recommendations concerning (...) the proper use of these agents. Searching The literature searches were conducted independently by two authors, who searched MEDLINE, Current Contents and HealthSTAR using the following medical subject headings and search terms: 'bisphosphonates', 'diphosphonates', 'glucocorticoids', 'steroids' and 'osteoporosis'. In addition, bibliographies of selected citations and review articles were examined. Unpublished information was obtained by handsearching abstracts from recent meetings (1998) of the American
Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Solomon D H, Kuntz K M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This paper compared three strategies, namely waiting, screening and treating, for the prevention of corticosteroid-induced osteoporosis in postmenopausal women with rheumatoid arthritis (RA
Screening for osteoporosis using easily obtainable biometrical data: diagnostic accuracy of measured, self-reported and recalled BMI, and related costs of bone mineral density measurements Screening for osteoporosis using easily obtainable biometrical data: diagnostic accuracy of measured, self-reported and recalled BMI, and related costs of bone mineral density measurements Screening for osteoporosis using easily obtainable biometrical data: diagnostic accuracy of measured, self-reported (...) ) for the screening of both osteoporosis and low bone mineral density (BMD; osteopenia plus osteoporosis) were examined. These were objective BMI, self-reported BMI and recalled BMI. The objective BMI equals the measured weight divided by the square of the measured height. The self-reported BMI equals the measured weight divided by the square of the self-reported height. The recalled BMI equals the recalled weight at age of 20 to 30 years divided by the square of the self-reported height. Type of intervention
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it has not been evaluated in the treatment of established postmenopausal osteoporosis.To test the efficacy and safety (...) tolerated in the treatment of women with established postmenopausal osteoporosis.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures.The (...) Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial.A total of 7705 women aged 31 to 80 years in 25 countries who had been postmenopausal for at least 2 years and who met World Health Organization criteria for having osteoporosis. The study began in 1994 and had up to 36 months of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 months of follow-up for serious adverse events.Participants were
Efficient patient identification strategies for women with osteoporosis Efficient patient identification strategies for women with osteoporosis Efficient patient identification strategies for women with osteoporosis Abbott T A, Mucha L, Manfredonia D, Schwartz E N, Berger M L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several strategies for the identification of women with osteoporosis were examined. Osteoporosis was defined as a T-score of less than -2.5 when using the bone mineral density (BMD) measurement, as recommended by the World Health Organization. The strategies comprised various combinations of central dual X-ray absorptiometry (DXA), periferal dual X-ray absorptiometry (pDXA) and Simple Calculated